Amphastar Pharmaceuticals Inc vs Centrus Energy Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Centrus Energy Corp trades at $190 (market cap $3.78B). The key difference: Centrus Energy Corp is far larger — about 4.4× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| AMPH | LEU | |
|---|---|---|
Market Cap | $863.95M | $3.78B |
Sector | Health | Energy |
52-Week High | $30.81 | $436.00 |
52-Week Low | $16.87 | $146.61 |
Enterprise Value | $1.26B | $3.09B |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Centrus Energy (LEU) trades at $191.37, up 7.49% in 24 hours, showing strong momentum amid bullish technical signals. Recent Q2 2026 earnings beat expectations with EPS of $0.77 versus $0.732 expected, though revenue growth is tempered by margin compression. The company secured a $900 million DOE contract and expanded its backlog to $4.5 billion, positioning it for long-term nuclear fuel demand. Analysts maintain a consensus buy rating with a $228.50 price target, reflecting optimism in its HALEU market dominance.
Outlook is positive due to government support and backlog visibility, but risks include high valuation (P/E 68.23), volatile cash flows, and execution challenges in scaling production. Investors should weigh growth potential against cost pressures and competitive dynamics in the nuclear sector.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →